142 related articles for article (PubMed ID: 37336652)
1. The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis.
Ergun Y; Akagunduz B; Karacin C; Turker S; Ucar G
Clin Breast Cancer; 2023 Aug; 23(6):567-575. PubMed ID: 37336652
[TBL] [Abstract][Full Text] [Related]
2. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
Lohmann AE; Soldera SV; Pimentel I; Ribnikar D; Ennis M; Amir E; Goodwin PJ
J Natl Cancer Inst; 2021 Nov; 113(11):1465-1475. PubMed ID: 33620467
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E
ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
5. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients.
Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K
Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in patients with small node-negative invasive breast cancer.
Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
10. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
11. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
14. Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
Kolberg HC; Loevey G; Akpolat-Basci L; Stephanou M; Fasching PA; Untch M; Bulsara M; Vaidya JS; Liedtke C
Rev Recent Clin Trials; 2017; 12(2):93-100. PubMed ID: 28155607
[TBL] [Abstract][Full Text] [Related]
15. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
Saleh RR; Nadler MB; Desnoyers A; Meti N; Fazelzad R; Amir E
Cancer Treat Rev; 2021 Nov; 100():102283. PubMed ID: 34530283
[TBL] [Abstract][Full Text] [Related]
16. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
18. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]